BioCentury | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

...cut about 26 positions, which will extend its cash runway into 2Q20. Targets: miR-29 - MicroRNA-29...
...S95010) MRG-201 (MiR-29) Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Cambrex Corp. Kala Pharmaceuticals Inc. miRagen Therapeutics Inc. MicroRNA-29 (miR-29) Permira...
BioCentury | Oct 21, 2017
Product Development

Naked ambition

Proof-of-concept data from miRagen Therapeutics Inc. show systemic delivery of its lead candidate can shrink lesions in cutaneous T cell lymphoma, and that its oligonucleotide platform can achieve broad distribution and a long half-life without...
BioCentury | Jul 18, 2017
Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular atrophy Studies in cell culture and mice suggest inhibiting miR-29b could help treat muscular atrophy. In a mouse skeletal myoblast cell line-based model of chemical-induced muscle cell atrophy, an miR-29b inhibitor tool compound...
BioCentury | Nov 3, 2016
Company News

Signal, miRagen deal

miRagen will merge with Signal to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain miRagen's name and trade on NASDAQ. The...
BioCentury | Nov 1, 2016
Company News

miRagen finds public path via Signal merger

...$0.50 on Tuesday. Jaime De Leon MRG-106 MRG-201 Myeloma Prognostic Risk Signature (MyPRS) test miRagen Therapeutics Inc. Signal Genetics Inc. MicroRNA-155 (miR-155) MicroRNA-29 (miR-29) MicroRNA-29b...
BioCentury | Dec 7, 2015
Clinical News

MiR-29: Phase I started

...by the first part but may be increased. miRagen Therapeutics Inc. , Boulder, Colo. Product: MiR-29...
BioCentury | Nov 11, 2015
Financial News

miRagen raises $41 series C

MicroRNA company miRagen Therapeutics Inc. raised $41 million in a series C round co-led by MRL Ventures and JAFCO. Other new investors Brace Pharma Capital and MP Healthcare Venture Management joined existing investors Atlas Venture,...
BioCentury | Nov 15, 2012
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lymphoma MicroRNA-29 (miR-29); c-Myc (MYC); histone...
...3 (HDAC3); enhancer of zeste homolog 2 (EZH2) In vitro and mouse studies suggest increasing miR-29...
...correlated with miR-29 downregulation. In the cells, small interfering RNA targeting HDAC3 and EZH2 increased miR-29...
BioCentury | Feb 16, 2012
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Aneurysm MicroRNA-29b (miR-29b) Studies in mice suggest inhibiting miR-29b could help treat abdominal aortic aneurysm. In a mouse model of...
BioCentury | Jul 28, 2011
Distillery Therapeutics

Indication: Infectious disease

...serum IFN-g levels and lower bacterial burdens than normal miR-29 signaling. In uninfected mice, decreased miR-29...
...include analyzing miR-29 and IFN-g levels in blood samples from chronic tuberculosis patients and evaluating miR-29...
Items per page:
1 - 10 of 18